drugset / Trial / NCT04682249
Systemic Chemotherapy, Apatinib Plus Sintilimab for Metastasis ICC
NaSingle-groupOpen-labelTreatment
Summary
This study were designed to verify the better method of survival for metastatic ICC. Since the traditional method for metastatic ICC was GEMOX(first-line treatment from NCCN guideline), our previous study found similar results from FOLFOX (second-line treatment from NCCN guideline) compared with GEMOX. Our current study were conducted for further investigation to verify the better method for metastatic ICC.
Timeline
- Start
- 2020-12-01
- Primary completion
- 2021-02-01
- Completion
- 2021-02-01
Outcome
Outcome not reported
Stopped (Enrollment): “no patients enrolled”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Leucovorin | Small molecule | — | — |
| Subject | Oxaliplatin | Small molecule | — | — |
| Subject | Rivoceranib | Small molecule | — | — |
| Subject | Sintilimab | Monoclonal antibody | — | — |
| Subject | fluorouracil | Small molecule | — | — |
Indications
No indication recorded.